Evidence that antibodies against recombinant SnSAG1 of Sarcocystis neurona merozoites are involved in infection and immunity in equine protozoal myeloencephalitis.
Sarcocystis neurona is the principal etiologic agent of equine protozoal myeloencephalitis (EPM). An immunodominant protein of S. neurona, SnSAG-1, is expressed by the majority of S. neurona merozoites isolated from spinal tissues of horses diagnosed with EPM and may be a candidate for diagnostic tests and prophylaxis for EPM. Five horses were vaccinated with adjuvanted recombinant SnSAG1 (rSnSAG1) and 5 control (sham vaccinated) horses were vaccinated with adjuvant only. Serum was evaluated pre- and post-vaccination, prior to challenge, for antibodies against rSnSAG1 and inhibitory effects on the infectivity of S. neurona by an in vitro serum neutralization assay. The effect of vaccination with rSnSAG1 on in vivo infection by S. neurona was evaluated by challenging all the horses with S. neurona merozoites. Blinded daily examinations and 4 blinded neurological examinations were used to evaluate the presence of clinical signs of EPM. The 5 vaccinated horses developed serum and cerebrospinal fluid (CSF) titers of SnSAG1, detected by enzyme-linked immunosorbent assay (ELISA), post-vaccination. Post-vaccination serum from vaccinated horses was found to have an inhibitory effect on merozoites, demonstrated by in vitro bioassay. Following the challenge, the 5 control horses displayed clinical signs of EPM, including ataxia. While 4 of the 5 vaccinated horses did not become ataxic. One rSnSAG-1 vaccinated horse showed paresis in 1 limb with muscle atrophy. All horses showed mild, transient, cranial nerve deficits; however, disease did not progress to ataxia in rSnSAG-1 vaccinated horses. The study showed that vaccination with rSnSAG-1 produced antibodies in horses that neutralized merozoites when tested by in vitro culture and significantly reduced clinical signs demonstrated by in vivo challenge.
Ellison
Siobhan
S
Pathogenes Inc, Fairfield, FL 32634, USA. sellison@pathogenes.com
Witonsky
Sharon
S
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood / Q000134:cerebrospinal fluid; D000953:Antigens, Protozoan / Q000494:pharmacology*; D004679:Encephalomyelitis / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control / Q000662:veterinary*; D005260:Female; D006734:Horse Diseases / Q000276:immunology / Q000469:parasitology* / Q000517:prevention & control; D006736:Horses; D008297:Male; D009500:Neutralization Tests / Q000662:veterinary; D015800:Protozoan Proteins / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology*; D012522:Sarcocystis / Q000276:immunology*; D012523:Sarcocystosis / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control / Q000662:veterinary*; D016037:Single-Blind Method; D014611:Vaccination / Q000662:veterinary
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C097089:p31 protein, Sarcocystis